Autopsy report · NCT00364533

A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety

“Slow enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 1 year 2 months before it stopped.
• 367 participants enrolled.
• Results were posted on the registry 1 year 7 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Sponsor type

Industry

Conditions

Arthroplasty

Interventions

Tapentadol IR (CG5503); Placebo; Oxycodone HCL IR; Tapentadol IR (CG5503)

Participants

367

Sites

77

Countries

Belgium, Canada, Finland, New Zealand, Spain, Sweden, United Kingdom, United States

Trials that died the same way

• EXCimEr Laser for Long lENgTh Lesions in Below-The-Knee Arteries Study
  “too slow enrollment” (95% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.